2023 Third Quarter Conference Call

November 6, 2023 • 4:30 PM ET

Nov 6, 2023 • 4:05 PM EST

Q3 2023 Quarterly Results

Quarter Ended Sep 30, 2023

Consolidated revenue increased 18% to $152 million

Clinical Services revenue increased 20% to $128 million

Advanced Diagnostics revenue increased 8% to $24 million

Net loss decreased 50% to $19 million

Adjusted EBITDA increased 129% to positive $3 million

Company Profile

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma
Services Division serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and Phoenix, Arizona; and CAP accredited laboratories in Cambridge, United Kingdom; Rolle, Switzerland; and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia. 

Latest 10-K

View Latest 10-K

NeoGenomics, Inc.

Nasdaq: NEO





Day Range

52 week Range

IR Contact Information

Investor Relations Jeffrey Sherman
Chief Financial Officer
T: 239.768.0600 x2726

Transfer Agent Broadridge Shareholder Services
1155 Long Island Avenue
Edgewood, NY 11717-8309
T: (888) 789-8606